SciSparc (SPRC) said Tuesday that the Israeli Medical Cannabis Agency at the Israeli Ministry of Health renewed an approval for the clinical trial of SCI-210 in children with autism spectrum disorder, or ASD.
The 30-day approval is expected to be extended upon final Israeli police approval, expected within the same timeframe, SciSparc said.
The SCI-210 clinical trial is a double-blind, randomized, placebo-controlled study at Soroka University Medical Center in Israel, involving 60 children aged 5 to18 with ASD, the pharmaceutical company said.
The 20-week trial will evaluate the efficacy and safety of SCI-210, which is a combination of a proprietary cannabidiol, or CBD, and CannAmide, against standard CBD therapy. The trial will focus on symptom management and therapeutic outcomes, SciSparc said, adding that it aims to launch SCI-210 in Israel first, with plans for international expansion pending regulatory approvals.
Price: 0.44, Change: -0.02, Percent Change: -4.98
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。